Key result
The 3-year adjusted rates of target-vessel failure were not significantly different among diabetic patients treated with four different contemporary drug-eluting stents.
Why the study?
Does the type of contemporary drug-eluting stent impact the rate of target-vessel failure in patients with diabetes mellitus undergoing percutaneous coronary intervention?
Does the type of contemporary drug-eluting stent impact the rate of target-vessel failure in patients with diabetes mellitus undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Four contemporary drug-eluting stents demonstrated comparable 3-year safety and efficacy outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in real-world clinical practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2021) conducted an editorial in Diabetes mellitus with coronary artery disease requiring PCI (n=7,823). Contemporary drug-eluting stents (cobalt chromium everolimus, biodegradable polymer biolimus, platinum chromium-everolimus, resolute zotarolimus) vs. Different types of contemporary drug-eluting stents compared against each other was evaluated on 3-year target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, and target-vessel revascularization). The 3-year adjusted rates of target-vessel failure were not significantly different among diabetic patients treated with four different contemporary drug-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: